View this email in your browser.

Hi there,

Eagle-eyed readers may have noticed some recent changes to our newsletters. We’ve had makeovers, a rebrand and even a new addition!

Our range of newsletters curated by our journalists showcase the scoops and stories shaping startup Europe. They’re also full of bonus news you won’t find anywhere else — not even on the Sifted site.

Find out more below — and of course, sign up!

Our latest Sifted report — available exclusively for Pro members — features the top entrepreneurs, investors and modern-day shamans vying to take the small but fast-growing world of psychedelics mainstream in mental health treatment.

If clinical trials go well, drugs like LSD and psilocybin could begin to replace antidepressants and other established treatments. Whoever patents these new treatments will be well placed to win a big chunk of the global $380bn mental healthcare market. Will the findings of a growing cohort of psychedelics startups be suitably mind-changing?

This report is exclusively for Sifted Pro members. Get in touch with the team today with code PSYCHREPORT10 for an exclusive discount!

Copyright © 2022 SIFTED (EU) LTD, All rights reserved.

Want to tailor what you receive from us?

Simply update your preferences to opt out of Sifted Updates, or you can unsubscribe from Sifted if you never want to hear from us again (this includes any newsletters and membership communications).